Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging

por Maksymowych, Walter P, Bolce, Rebecca, Gallo, Gaia, Seem, Emily, Geneus, Vladimir J, Sandoval, David M, Østergaard, Mikkel, Tada, Kurisu, Baraliakos, Xenofon, Deodhar, Atul, Gensler, Lianne S
Publicado 2022

Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase...

por van der Horst-Bruinsma, Irene E., de Vlam, Kurt, Walsh, Jessica A., Bolce, Rebecca, Hunter, Theresa, Sandoval, David, Zhu, Danting, Geneus, Vladimir, Soriano, Enrique R., Magrey, Marina
Publicado 2022

Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2)

por Orbai, Ana-Maria, Gratacós, Jordi, Turkiewicz, Anthony, Hall, Stephen, Dokoupilova, Eva, Combe, Bernard, Nash, Peter, Gallo, Gaia, Bertram, Clinton C., Gellett, Amanda M., Sprabery, Aubrey Trevelin, Birt, Julie, Macpherson, Lisa, Geneus, Vladimir J., Constantin, Arnaud
Publicado 2020